Related Experiment Video
Updated: Jul 4, 2026
06:58
A Structured Rehabilitation Protocol for Improved Multifunctional Prosthetic Control: A Case Study
Published on: November 6, 2015
[Experience with Dohlman-Doane keratoprosthesis: case reports]
Andressa Prestes Stolz1, Sérgio Kwitko, Melissa Manfroi Dal Pizzol
1Setor de Córnea e Doenças Externas, Serviço de Oftalmologia, Hospital das Clínicas de Porto Alegre, Porto Alegre, RS, Brasil.
Arquivos Brasileiros De Oftalmologia
|June 3, 2008
Summary
The Dohlman-Doane keratoprosthesis (KPro) offers a viable solution for corneal blindness, especially in non-immune conditions. This artificial cornea provides significant visual improvement in eyes with poor prognoses for traditional corneal transplants.
Area of Science:
- Ophthalmology
- Corneal Surgery
Background:
- Corneal blindness presents a significant challenge, particularly in cases with a history of severe injury or graft failure.
- Traditional penetrating keratoplasty may have a poor prognosis in such complex cases.
Observation:
- This study evaluated 9 eyes in 8 patients receiving the Dohlman-Doane type 1 keratoprosthesis (KPro).
- Patients had severe corneal disease, including alkali burns, graft failure, Stevens-Johnson syndrome, and thermal injury, with pre-operative best-corrected visual acuity (BCVA) of hand motions or worse.
- Three patients had pre-existing glaucoma requiring Ahmed valve implantation.
Findings:
- 88.9% of eyes achieved a BCVA of 20/100 or better, with 44.4% reaching 20/40 or better.
- Postoperative complications included posterior capsule opacity (3 eyes), retroprosthetic membrane (3 eyes), glaucoma (2 eyes), corneal melting (1 eye), and fungal endophthalmitis (1 eye), all managed with specific interventions.
- The Dohlman-Doane KPro demonstrated effectiveness in restoring vision in challenging corneal blindness cases.
Implications:
- The Dohlman-Doane KPro is a promising alternative for corneal blindness with poor prognoses for conventional penetrating keratoplasty.
- A key advantage is the avoidance of systemic immunosuppression.
- Optimal outcomes were observed in patients with non-immune corneal diseases.